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Abstract 
Background 
Atopic eczema (also known as eczema) is a chronic, inflammatory skin condition that often 
afflicts patients’ health and wellbeing. The Harmonising Outcome Measures for Eczema 
(HOME) initiative recommends that “long-term control of eczema” is measured in all clinical 
trials 3 months or longer in duration. However, little has been published on what eczema 
control means to those living with or treating atopic eczema. 
Objectives 
To i) develop understanding of what eczema control means to patients, carers and clinicians 
and ii) explore the feasibility and acceptability of different ways of measuring eczema 
control in the long-term. 
Methods 
Online focus groups explored patients/carers experiences in the UK, USA, the Netherlands, 
France, Sweden and Japan, and an international online survey gathered views of clinicians. 
The Framework Method was used to analyse the focus groups and thematic analysis was 
used to analyse survey data. All findings were integrated into a theoretical framework to 
create overarching themes that cut across these diverse groups. 
Results 
Eight focus groups with patients (16 years+) and eight groups with carers of children took 
place (N=97). Sixty-two people took part in the survey. Eczema control was described as a 
multifaceted construct involving changes in disease activity, the treatment and 
management of the condition, and psychological, social and physical functioning. Patient 
/carer measurement allows personal accounts and frequent measurement, whilst clinician 
measurement was deemed less subjective. The burden on patients/carers and issues for 
analysing and interpreting data should be considered. 
Conclusions 
This study formed the basis of judging the content validity and feasibility of measurement 
instruments/methods to assess control of eczema in clinical trials. This online approach to 
an international qualitative study is an example of how core outcome set developers with 
limited resources can engage with multiple stakeholder groups on an international basis to 
inform consensus meeting discussions. 
Keywords 
Eczema, atopic dermatitis, qualitative, long-term control, content validity, item generation, 
patient perspective 
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Introduction 
Atopic eczema (syn: eczema, atopic dermatitis) is a chronic, inflammatory skin condition 
characterised by periods of remission and relapse 1. An international survey found that 75% 
of patients and caregivers rated being able to effectively control their eczema as the most 
important factor contributing to an improvement to their quality of life 2.   
The Harmonising Outcome Measures for Eczema (HOME) initiative is an international 
collaboration developing a consensus and evidence-based core outcome set for atopic 
eczema clinical trials 3-7. The HOME initiative recommends that “long-term control of 
eczema” is measured in all clinical trials 3 months or longer in duration. 3, 5.  The first step 
for HOME to be able to recommend instrument(s) to measure this domain was to conduct 
international studies to gather patient and clinician perspectives on long-term control of 
eczema. 
Content validity is essential for an instrument to be selected for inclusion in a core outcome 
set and is defined as “the degree to which the content of a health related patient reported 
outcome instrument is an adequate reflection of the construct to be measured”8 9.A key 
initial step in establishing content validity is defining the construct to be measured. A 
construct is a mental abstraction that provides a common language that has a shared 
meaning to help us communicate in a clear and precise manner. A conceptual model of the 
construct is then developed to allow  judgement of whether an instrument adequately 
reflects the concepts relevant to the construct of interest 9. Qualitative research helps to 
build a definition of a construct that authentically and comprehensively reflects patient 
experiences 10.  
This study aimed to facilitate evidence-based discussions within HOME about how to define 
and measure “long term control of eczema” and enable assessment of the content validity 
of existing outcome measurement instruments. The study objectives were (1) to understand 
what long-term control of eczema means to people living with atopic eczema (including 
adults with eczema and parents/carers of children with eczema) and people treating eczema 
(clinicians/researchers) and, (2) to explore the potential feasibility and acceptability of 
different ways of measuring long-term control of eczema.  
 
Methods 
Study Design  
To obtain the perspectives of patients/carers and clinicians treating atopic eczema, online 
focus groups and an online survey were carried out respectively.  
Online focus groups with patients/carers 
Participant selection 
Adults with eczema and parents, legal guardians or carers of children with eczema were 
included in the online focus groups, hereafter referred to as patients/carers for brevity. The 
term ‘patients’ refers to people who are seeking or receiving healthcare11. As we recruited 
through a variety of different platforms and not necessarily healthcare settings, participants 
in these studies could more correctly be referred to as ‘people with eczema’. However, we 
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sometimes refer here to ‘patients’ for brevity. The sampling strategy aimed to purposefully 
include a diversity of participants regarding age, sex, ethnicity, eczema severity and disease 
duration, but convenience was also a factor 12. Recruitment was via social media or 
approaching patients in clinics, and varied by country (See Table 1 in Supplementary 
Materials for details of methods by country).  
Procedures and materials 
Online focus groups were conducted via text-based chatroom websites between August 
2016 and June 2017 in the UK, the Netherlands, France, Sweden, USA and Japan. Local 
teams conducted the data collection in their own country and native language, supported 
by the UK team, following the format of the initial UK-based focus groups. Full details of the 
procedure of the UK focus groups has been described elsewhere 13. Table 1 in 
Supplementary Materials highlights key aspects of the procedure for each country. Each 
focus group followed a common semi-structured topic guide that was developed by the UK-
based authors (Figure 1 in Supplementary Materials). Questions were open ended, for 
example, “How would you decide if a treatment has been working well or not?” and 
followed up with prompts to elicit further information from participants. The term “long-
term control” was initially avoided by the facilitators to allow individuals to refer to this 
concept using language that was meaningful to them.  
Analysis 
The principles of Framework Analysis were used to analyse the transcripts thematically 14. 
Framework Analysis is a method that sorts data into key themes using the five steps of 
familiarisation, identifying a theoretical framework, indexing, charting, and mapping and 
interpretation14. Each country used a thematic framework to map findings to the sub-
themes that were based on the findings from the UK focus groups and also highlight findings 
that did not fit within the framework 13. This was done in the native language of the 
researchers. The detailed UK findings were not shared with the other groups until they had 
analysed their findings. A summary and key quotes were produced in English by each 
country. The UK team collated and compared the data from all countries in a thematic 
framework. Any areas of uncertainty were discussed with the researchers who collected the 
data. 
Online survey of HOME membership 
Participant selection 
All members of HOME were invited to participate. HOME is an open-invitation, 
international, multi-stakeholder group including clinicians (mainly dermatologists), 
methodologists, patients, patient representatives and the pharmaceutical industry 
(http://www.homeforeczema.org/).  
Materials and procedures  
This online survey took place during September and October 2016 using SurveyMonkey Inc. 
software 15. Using mainly open questions with free text responses, participants were asked 
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what they considered to be long-term control of eczema and their views on different ways 
of measuring long-term control (Figure 2 in Supplementary Materials) identified from a 
systematic review 16.   
Analysis 
Thematic analysis was used to analyse textual data 17. J.R.C compiled the themes and I.N 
and L.H reviewed the themes, which were then discussed and revised.  
Combining the focus group and survey findings 
L.H and J.R.C combined the themes from the online patient/carer focus groups and the 
clinician survey into an overarching thematic framework. These themes were then 
compared with original data sources and initial coding confirmed with all authors. 
 
Results 
Participant Characteristics 
Sixteen online focus groups took place including 97 patients/carers across six countries. 
Table 1 provides participant demographics.  
Sixty-two out of 251 HOME members from sixteen countries completed the online survey, a 
response rate of 25%. Most (81%) were clinicians, plus 5 methodologists/non-clinical 
researchers and 7 patient representatives. Since this survey principally represents the views 
of clinicians, this group is hereafter referred to as clinicians for brevity. Sixteen countries 
across six continents were represented (Fig. 1).  
Overarching themes 
The results can be structured into two overarching themes; i) long-term control as a 
multifaceted construct and ii) long-term control is complex to measure. Illustrative quotes 
that link themes to the data are presented in Table 2 and Table 3. 
1) Long-term control as a multifaceted construct 
Most participants described multiple related aspects of atopic eczema when thinking about 
‘what is long-term control of eczema?’ which divide into four key sub-themes (Fig. 2). 
1a) Long-term control as disease activity 
Patients/carers and clinicians frequently described long-term control as a reduction in 
disease activity. Signs and symptoms such as the level of itch, pain, and redness were often 
mentioned, although patients with more severe atopic eczema were also concerned about 
complications such as infection and bleeding. Clinicians used terms such as reduced 
intensity, minimal signs and/or symptoms or minimal disease activity. Differences in some 
symptoms by country were noted; for example only participants in France discussed 
“smoothness of skin” as an indicator of control.  
Disease activity in relation to flares of activity was also described. A reduction in the 
intensity, number, frequency and duration of flares were all parameters suggested as 
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indicators of disease control. However, the concept of “flares” was not seen as universally 
useful, as a flare was difficult to define and did not always correlate with disease activity. 
For example, those with a continually high level of disease activity may not experience 
flares, despite having uncontrolled atopic eczema.  
1b) The experience of long-term control goes beyond the skin 
A positive impact on daily activities was considered important to patients/carers and 
clinicians.  Patients/carers reported a wide range of daily activities that were affected by 
atopic eczema, but these varied among countries. For example, in the UK, washing, exercise, 
and clothing choice were discussed, whereas in Japan it was disturbance of concentration 
while reading books and watching TV. Scratching, sweating, pain, sleep disturbance and lack 
of ability to concentrate were amongst the ways that patients and carers described atopic 
eczema having an impact on their daily life.   
The emotional impact of uncontrolled eczema was raised by patients/carers, who often 
reported high levels of distress when eczema was uncontrolled. Feeling frustrated, 
miserable and “stressed” when eczema was uncontrolled, apprehensive about the return of 
flares, and the social impact on patients and their families were all mentioned. Feeling 
embarrassed or receiving comments from others were discussed, particularly when the 
eczema was on a visible area such as the face. Some patients/carers felt that eczema 
controlled their lives and prevented social activities, such as visiting friends and family and 
school attendance. Clinicians also described the impact of uncontrolled eczema on patient’s 
quality of life.  
1c) Long-term control linked to treatment and management decisions 
Long-term control was also linked to treatment use by patients/carers and clinicians in all 
countries. Reducing treatment or returning to maintenance treatment were indicators of re-
gaining control. Using only maintenance treatment and ability to self-manage were 
indicators of ongoing control. Seeking help from a doctor, stepping up treatment, or 
increasing the amount or frequency of treatment were all described as indicators that the 
disease was uncontrolled. 
1d) Control is an individual experience 
Control of eczema was largely considered to be an individual experience. Individual 
patients/carers reported different aspects of the disease as being representative of a lack of 
control, such as specific symptoms, the need to increase treatment, or the impact on 
particular aspects of life. The level at which disease activity or impact represents control 
varied between individual patients/carers. Some expressed that feeling the eczema has 
“completely receded” would represent control, whereas for others, a reduced and 
acceptable level of disease activity was considered controlled. Clinicians often linked control 
to being what is acceptable to the individual patient such as “can live with” or that is 
“acceptable to the patient”.  
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1) Long-term control is complex to measure 
Patients/carers and clinicians also discussed what they felt was important when measuring 
long-term control, and the sometimes opposing views reflect the complexity involved in 
measuring this multi-dimensional construct. 
2a) Who should measure long-term control? Experience vs. standardisation 
The majority of patients/carers felt strongly that they were best placed to understand and 
measure their own (or their child’s) eczema, and could measure disease activity between 
visits to their doctor. Some patients/carers felt clinicians should also measure the eczema, 
as they have expertise, experience and are less likely to be subjective. Clinicians 
acknowledged the importance of patient-reported outcomes as an important way of 
capturing aspects of the disease that cannot be assessed by a clinician, but for measuring 
long-term control in clinical trials they were also concerned about potential for bias, 
reproducibility and scientific acceptability, and discrepancies between patient reported and 
clinician reported outcomes. These findings point to a trade-off between measuring aspects 
of control that only patients/carers can assess that captures their everyday experience 
versus having a more standardised method of measuring long-term control that can be 
assessed by independent observers.  
2b) The burden and feasibility of measuring long-term control  
Many patients/carers raised concerns about the time and effort required to measure long-
term control comprehensively, whereas some, particularly parents of children with eczema, 
were prepared to go to great lengths to ensure that the level of control was captured 
accurately and frequently. Clinicians also highlighted the potential burden of frequent 
measurement on patients/carers resulting in the generation of large amounts of potentially 
redundant data. In the USA, the Netherlands and the UK, patients/carers discussed the role 
that technology such as smartphone applications and photographs could help them 
measure their eczema more frequently and for long periods of time. 
 
Discussion 
This study suggests atopic eczema control is a multifaceted construct involving changes in 
the signs and symptoms of eczema, psychological, social and physical functioning, and the 
treatment and management of the condition. Indicators of control and the acceptable level 
of control can vary between individuals. Both patient-reported and clinician-reported 
outcomes were considered important when measuring atopic eczema control.  
The multi-dimensional nature of atopic eczema control is reflected in a systematic review of 
how long-term control has previously been captured in clinical trials 16. Ninety-one percent 
of trials captured long-term control by including repeated measurement of outcomes, such 
as clinical signs, quality of life and itch, whilst the use of atopic eczema medications or flares 
(most commonly measured as time to first flare or number of flares) were reported in 
approximately a quarter of trials 16. Although clinical trials have captured individual sub-
domains identified in this study as being important to patients/carers and clinicians, long-
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term control has not routinely been captured as a unified construct using a single 
instrument.  
There is no agreed definition of an eczema flare, although many definitions have been 
proposed and used in trials often with little validation 18, 19. However, our study suggests 
that eczema control should be viewed by patients/carers and clinicians as a broader concept 
than these previous definitions. Furthermore, we identified how treatment escalation in 
response to a loss of control is subject to differences between individuals depending on 
their access to healthcare resources, concerns they may have about using certain 
treatments, and the type of treatment (i.e. topical or oral) that they are using. 
The variability between patients regarding the level of control considered to be acceptable, 
highlighted by both patients/carers and clinicians, presents a challenge for measuring 
eczema control. What constitutes control for an individual with eczema may be driven by 
their expectations of the disease course, their treatment, and the degree to which they have 
accepted having the disease and the lack of a cure. It is possible that expectations about the 
level of disease control in eczema may be altered in the future by advances in treatments. It 
is important to consider how the expectations of the patient/parent may impact measures 
of eczema control. For a patient/parent reported outcome, there may be changing 
standards depending on level of adjustment to the condition. 
Both patient/carer and clinician reported outcomes were considered important in the 
measurement of eczema control. There is an increasing acceptance within the medical 
community of patient-reported outcome measures and a patient-centred approach to 
healthcare and a review showed that patient/parent-reported symptoms were reported in 
78% of atopic eczema clinical trials 20.  However, with both patient and clinician reported 
measures, consideration of the burden and feasibility of measurement is needed.  
Strengths and Limitations 
This study was a pragmatic approach to collecting qualitative data on an international scale 
from a range of stakeholders. The innovative online approach provides a low-cost and rapid 
alternative to other more traditional methods of opinion gathering such as face-to-face 
focus groups, whilst still creating a supportive environment where discussion could be 
prompted. However, one challenge with the online data collection is that the responses 
could be brief. The learning from the initial UK-based online focus groups was shared with 
other authors running the subsequent online focus groups in other countries to elicit more 
detailed responses and prompt a coherent discussion amongst participants 13. A convenient 
online survey using mainly open text responses was used to gain the clinician perspective. 
This method was considered appropriate because HOME members are familiar with the 
concepts being discussed and responses were generally clear and relevant. Only 25% of the 
HOME membership took part in the survey, and it is possible that views may not have been 
representative of the entire HOME membership. However, the findings from this study 
informed decisions at the next HOME meeting, therefore allowing HOME members who did 
not participate in the survey further opportunity to input into HOME consensus decisions. 
Although the sampling was partially convenience-based due to restraints on time and 
resources, participants with diverse characteristics were still included. However, people 
with mild atopic eczema and primary care practitioners treating atopic eczema were 
underrepresented. These two groups respectively constitute the majority of people with 
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eczema and deliver the majority of atopic eczema care 21. The availability of resources also 
resulted in a predominance of participants in Western countries, and further efforts are 
needed to engage patients, parents and clinicians across different continents to ensure the 
cross-cultural validity of the HOME initiative’s recommendations.  
Implications and future directions  
To our knowledge, this is the first international qualitative study to investigate what long-
term control of eczema means to patients, carers and clinicians. It provides evidence for 
developing a standardised, consensus-based definition of long-term control of eczema by 
the HOME core outcome set initiative. The implementation of the core outcome set will 
allow standardisation of measures across atopic eczema trials and increase the ability to 
synthesis and comparing results from multiple trials.  
Understanding long-term control from different stakeholder perspectives will lead to 
improvements in how long-term control is measured in clinical trials. This study directly 
informed discussions about the content validity and feasibility of different methods of 
measuring long-term control at the HOME V consensus meeting, allowing the HOME group 
to move towards consensus on standardising the measurement of this domain 7. Those 
assessing the quality of existing measurement instruments or developing measurement 
instruments of atopic eczema control could use the findings of this study to inform decisions 
about the content validity of the instrument. The results of this study are currently being 
used to inform the development of an eczema control instrument. Although this study was 
aimed to inform measurement of eczema control in clinical trials, it may also be appropriate 
to inform measurement in routine clinical settings. 
 
Conclusions 
Patients, carers and clinicians across multiple countries view long-term control of eczema as 
a multi-faceted construct involving changes in disease activity, the treatment and 
management of the condition, and psychological, social and physical functioning. This online 
approach to an international qualitative study is an example of how core outcome set 
developers with limited resources can engage with multiple stakeholder groups on an 
international basis to inform consensus meeting discussions.  
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Table 1 
Demographic info of online focus group participants 
 UK The 
Nether
lands 
France Sweden USA Japan All 
countries 
N of participants 37 15 9 15 8 13 97 
Patients, N 19 7 5 7 4 10 52 
Parents, N  18 8 4 8 4 3 45 
N of focus groups 6 2 2 2 2 2 16 
Self or parent reported sex, n (%) 
Male 13 6 4 4 0 8 35 
Female 24 9 5 4 8 5 55 
Unknown 0 0 0 7 0 0 7 
Self or parent reported age in years, n (%) 
≤5* 12 5 0 4 0 2 23 
6-11* 5 1 4 2 3 1 16 
12-15* 0 2 0 2 1 0 5 
16-25 7 0 0 2 3 4 16 
26-40 6 1 2 2 0 0 11 
>40 6 6 3 2 1 6 24 
Unknown 1 0 0 1 0 0 2 
Self or parent reported ethnicity, n (%) 
White 33 14 9 15 4 0 68 
Asian 1 0 0 0 2 13 15 
Black 0 0 0 0 1 0 1 
Mixed 3 1 0 0 1 0 5 
Unknown 0 0  0 0 0 0 0 
Self or parent reported years since eczema diagnosis 
≤5 13 5 1 5 0 3 27 
6-11 6 1 3 2 3 0 15 
12-15 0 2 0 1 0 2 5 
16-25 6 0 2 3 4 4 19 
26-40 5 2 1 3 0 2 13 
>40 5 5 1 1 1 2 15 
Unknown 2 0 1 0 0 0  3 
Self or parent reported current disease severity, n (%) 
Clear 2 0 1 0 0 0 3 
Almost clear 4 2 2 3 0 2 13 
Mild 8 4 5 7 1 4 29 
Moderate 16 5 1 3 3 4 33 
Severe 6 4 0 1 4 3 18 
Very severe 1 0 0 0 0 0 1 
Unknown 0 0 0 1 0 0  1 
*Participants were carers for all aged under 16 years.  
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Table 2 
Illustrative quotes for Theme 1 
Theme 1: Long-term control is a multifaceted concept 
Sub themes Illustrative quotes 
(patients/carers) 
Illustrative quotes 
(clinicians/researchers) 
1a) Disease 
activity 
  
Improved signs and 
symptoms 
I feel long-term control means 
less pain, less itch, less scratch – 
adult, Japan 
 
Achievement and maintenance 
of a low level of symptoms and 
signs of AD over time – clinician, 
Germany 
Flares My skin really hates me. Usually 
when it has completely receded, 
I am still waiting for this eczema 
to die down completely. – adult, 
UK 
A treatment plan that prevents 
flares for a longer period of time 
(years) – Clinician, Denmark 
1b) Beyond the 
skin 
  
Emotional impact Her whole demeanour changes 
too - weepy, fiery temper, 
generally sad.  – carer, UK 
 
In case of big flare, my skin gets 
worse and worse spontaneously 
even though I do not scratch. I 
feel quite depressed in this 
process – adult, Japan 
 
Social impact Children at school can be 
quite unkind when it's sore 
looking – carer, UK 
 
How they interact, their 
developmental markers, how 
much socialisation they get, for 
us when his skin is bad it's the 
socialising and getting out of the 
house that suffers – carer, UK 
Re-establishment of normal 
sleep patterns Re-establishment 
of normal social activities and 
ADLs [activities of daily living]. 
Re-establishment of normal 
family dynamics – clinician, 
South Africa 
Family impact “center of our lives”  - carer, USA 
 
 
Effect on my day 
(including the 
impact of 
scratching and loss 
of concentration) 
I would say how much I feel my 
eczema is bothering me in 
everyday life, what you might be 
doing differently because of your 
eczema – adult, UK 
Living with eczema of a tolerable 
level without flares that start to 
interfere with work and play – 
clinician, UK 
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and then I'd spend my time 
staring into space, itching, 
feeling sorry for myself and 
unable to snap out of it – adult, 
UK 
 
Permanent sensation of 
scratching non-stop - adult, 
France 
Increase in symptoms, itching, 
scratching behaviour that may 
impact on daily activities / sleep 
and quality of life. – clinician, UK 
Sleep disturbances It’s important to me to create 
more rest in the long-term and 
to be able to sleep well. Then I 
have more energy to do my daily 
things – adult, The Netherlands 
 
How much trouble I have, for 
example, I get a problem with 
sleep when the eczema is at 
its worst – adult, Sweden 
Disease improvement that no 
longer affects sleep and daily 
function that lasts for more than 
6 months – researcher, US 
 
1c) changes in 
treatment and 
management 
  
Using only 
maintenance 
treatment 
can return to normal 
maintenance routines – adult, 
UK 
No itch; controlled by emollient 
only. –clinician and researcher, 
Japan 
Stepping down 
treatment 
…I realize long-term control by 
frequency of TCS application. 
While maintaining by tapering 
frequency of TCS, I recognize 
long-term control by no flare 
despite less frequent TCS.  – 
adult, Japan 
The end of using the rescue 
medication, because overall 
disease severity is back to pre-
flare levels. – clinician, Germany 
Self-management 
of the eczema 
I guess so. We see the doctor 
more during a bad patch, but 
when I can manage it at home 
we see him less. I only go to him 
if I need him when it's beyond 
me level of helping. – carer, UK 
Self-management of control of 
eczema flares – researcher, 
Germany 
1d) An individual 
experience 
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A level of eczema 
acceptable to me 
I think everyone has his own 
definition of ‘control’. For me the 
bar is set fairly low. I will have 
itch every day and I accept it. As 
long as it’s not constantly there. 
– Adult, Netherlands 
Over time I have been taught by 
patients that individually, 
patient satisfaction with their 
skin and the treatments used 
varies enormously and what for 
me as a clinician is poor control 
is entirely acceptable for a 
patient who has reached a level 
of control that they feel 
manageable and which does not 
interfere with their life style 
psychosocial health or general 
health (read adverse effects 
especially). How does one 
integrate measures of this sort 
into trials and give them 
meaning? – clinician and 
researcher, South Africa 
Note. Some quotes have been translated into English from another language. Spelling and 
grammar has been edited for ease of reading. 
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Table 3 
Illustrative quotes for Theme 2 
Theme 2: Long-term control is complex to measure 
Sub themes Illustrative quotes from 
patients/carers 
Illustrative quotes from 
clinicians/researchers 
2a) Who measures 
long-term control 
You know your own body and 
eczema best, a doctor has expertise 
and experience. – adult, The 
Netherlands 
 
Has to be you. SO subjective a 
topic, and nurses' [and] doctors can 
only observe so much - and not the 
effects it has personally! - adult, UK 
Recording of observed signs in 
parallel with patient-reported 
symptoms and QoL will add 
information. Taken together, 
these measures would 
probably be judged by many 
as more robust and valid. – 
clinician and researcher, 
Sweden 
 
These measures might be 
more standardized across a 
population. – clinician and 
researcher, United States 
2b) The burden 
and feasibility of 
measuring long-
term control 
Again it depends on each child, but 
certainly more frequently than the 
usual 3 months between consultant 
visits; we can be fine in the 
morning as horrendous by bedtime.  
– parent, UK 
 
I do not want to observe every bad 
aspect of my skin, as it makes me 
depressed. I never want to take a 
picture of worsening skin.  I think 
we should look at the better 
aspects. – adult, Japan 
 
The time interval might depend on 
individuals needs and severity of 
eczema. – adult, Sweden 
Motivation of patient to 
describe regular frequent 
diary is needed.  Reliability 
that the patient regularly and 
surely describe each outcome 
is doubtful. – clinician, Japan 
 
[Discussing concept of well-
controlled weeks] Difficult to 
define/assess, Might be 
difficult to assess in a 
standardised way and might 
result in difficulties to merge 
data/compare trials - clinician 
and researcher, Sweden 
Note. Some quotes have been translated into English from another language. Spelling and 
grammar has been edited for some quotes for ease of reading. 
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Figure 1 
Country of residence for online survey respondents. 
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Figure 2 
What does atopic eczema control mean to patients, parents, and clinicians? 
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